A Double-blind Study of the Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog in Subjects With Type 1 Diabetes Including Assessments of Safety and Injection Site Toleration
Latest Information Update: 07 Nov 2021